



Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.







Price	52 week low	52 week high	Total shares outstanding	Market cap	Exchange market
99.62	94	134.63	2530 Millions shares	252 Billions	New York Stock Exchange

The dividend price rating*
8.52/10

TTM

Blue Chips	Yes	✓
Brand ranking**	405	✓
10 year annualised Revenue growth	2.67%	✗
10 year annualised Net Income growth	19.82%	✓
10 year annualised EPS growth	22.30%	✓
Price earnings ratio	20.83	✓
Net Profit Margin	19.22%	✓
Dividend payout ratio	63.72%	✓
Total Yield % (Dividend yield+share buybackyield)	3.62%	✗
Return on equity	29.27%	✓
Return on Assets	10.34%	✓
Return on Invested Capital	15.95%	✓
Debt to equity	0.86	✓
Debt to assets	0.32	✓
Price to book ratio	5.69	✗
Fair Value (Morning star)	120	✓
Economic Moat (Morningstar)	Wide	✓
Long term debt rating (Moody's)	A1	✓
Short term debt rating (Moody's)	P-1	✓
ESG Score	73.67	✓

Stock beats the ref. index for the last 10 years	✗
steady revenue ?	✓
Steady net income ?	✓
Steady profit margin positive ?	✓
Steady FCF ?	✓
steady dividends or increasing ?	✓
Nb of shares decreasing ?	✓



*The dividend price rating is explained here

**Brand ranking source